Navigation Links
Phase II Clinical Trial Results Encouraging for PA-Based Women's Health Company
Date:1/11/2011

WAYNE, Pa., Jan. 11, 2011 /PRNewswire/ -- FemmePharma Global Healthcare, a privately held women's health company dedicated to improving the quality of life for women, today announces completion of its Phase II clinical dose ranging/safety trial with FP 1097 in women suffering from urinary incontinence or overactive bladder (OAB).

The Phase II FP 1097 trial demonstrated that drug can be delivered to the bladder via intra-vaginal administration successfully. The clinical trial showed a statistically significant 25 percent reduction of micturitions and a 75 percent reduction of incontinence episodes. Treatment-related adverse events were low with no serious adverse events and all subjects completing the trial. Over 50 percent of the patients on FP 1097 achieved total continence.

Based on the results, FemmePharma Global Healthcare was granted permission to proceed to a pivotal Phase III trial by the Food and Drug Administration (FDA). In addition the FDA will grant FemmePharma 505B1 filing status for FP 1097.

According to published reports, it is estimated that more than 30 million Americans (mostly women) experience OAB. IMS Healthcare estimates that the OAB prescription market in the United States exceeds $2.0 billion annually while the total worldwide market including drugs, diapers and devices exceeds $7.0 billion annually.

"The encouraging safety and efficacy results from this randomized study of FP 1097 provides a basis to advance this innovative product into Phase III clinical development," said Gerianne DiPiano, founder, President and CEO of FemmePharma Global Healthcare, Inc.


'/>"/>
SOURCE FemmePharma Global Healthcare
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Enobia Announces Successful Completion of Phase II Juvenile Study of ENB-0040, a Bone Targeted Enzyme Replacement Therapy
2. Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients
3. MacroGenics Initiates Phase I Clinical Trial of MGAH22 for Patients With HER2-Expressing Solid Tumors
4. Juventas Therapeutics Initiating Phase II Clinical Trial of JVS-100 for Treatment of Critical Limb Ischemia
5. Tolerx Initiates Phase 1 Clinical Trial of TRX518, a First-in-Class anti-GITR Antibody for the Treatment of Cancer
6. Spherix Phase 2 Trial with D-tagatose Determines Minimum Dose for HbA1c and Triglycerides
7. GeNO LLC Initiates Phase 2 Trial For Nitric Oxide Delivery System
8. Onyx Pharmaceuticals Announces Positive Complete Results From Carfilzomib Phase 2b Study
9. YM BioSciences Reports Positive Interim Data Including Substantial Anemia Response from Phase I/II Trial of JAK1/JaK2 Inhibitor CYT387
10. Early Safety Results Promising for Phase I/II Trial of Gene Therapy Treatment of Hemophilia B
11. Oncothyreon Reports Positive Data from Phase 1 Clinical Trial of PI3-Kinase Inhibitor PX-866 in Patients with Relapsed or Refractory Solid Tumors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... Aug. 20, 2014 Neurotrope, Inc. (OTCQB: ... conference call to provide an update on Company ... daylight timeDial-in numbers:(888) 505-4369 (U.S. and Canada) or ... cast: www.neurotropebioscience.com , under "Investor Relations"The teleconference replay ... through September 2, 2014 at (888) 203-1112 (U.S. ...
(Date:8/20/2014)... 20, 2014 Not long ago, it ... should be performed late in the development cycle – ... current regulatory trends suggest that, like many things GxP, ... In recent years, multiple drug sponsors have been required ... specific questions during phase I/II. It’s not only clinical ...
(Date:8/19/2014)... 2014 One of the major ... an inadequate vascular supply. Nutrient and gas transport ... is critical for successful regeneration and integration into ... deficiencies in vascularization and promote angiogenesis in a ... scaffold design and architecture, and enhancing scaffolds with ...
(Date:8/19/2014)... Research and Markets  has announced the addition of the ... Report" report to their offering. This ... (SOFCs) in US$ Thousands. The report provides separate comprehensive analytics ... Europe , Asia-Pacific , and Rest ... period 2012 through 2020. Market data and analytics are derived ...
Breaking Biology Technology:Neurotrope To Host Conference Call 2Are Extractable and Leachables going Phase-Appropriate? New Webinar Hosted by Xtalks 2Vascularization in Tissue Engineering Highlighted at 12th New Jersey Symposium on Biomaterials Science 2Global Solid Oxide Fuel Cells (SOFCs) - Strategic Business Report 2014 2
... 11 The following is,GlaxoSmithKline,s (NYSE: ... by the,Institute for Clinical Evaluative Sciences (ICES) ... with,Diabetes"., GSK believes that the ICES ... database has significant limitations and generates misleading,conclusions ...
... today announced its,latest findings regarding the virus replikin ... analysis has found that the prevalence,of these sequences ... now have been found in China. These statistics ... linked to the lethality of,influenza viruses. When factored ...
... Dec. 11 Lucid, Inc., (http://www.lucid-tech.com ), a ... Dr. Colin Stahel as Director, Asia Pacific Region., ... for the newly created,position based on his extensive ... of experience in the development of medical,technology and ...
Cached Biology Technology:GlaxoSmithKline Responds to JAMA Article on the ICES Thiazolidinediones and Cardiovascular Outcomes in Older Patients with Diabetes 2GlaxoSmithKline Responds to JAMA Article on the ICES Thiazolidinediones and Cardiovascular Outcomes in Older Patients with Diabetes 3GlaxoSmithKline Responds to JAMA Article on the ICES Thiazolidinediones and Cardiovascular Outcomes in Older Patients with Diabetes 4GlaxoSmithKline Responds to JAMA Article on the ICES Thiazolidinediones and Cardiovascular Outcomes in Older Patients with Diabetes 5Lethal Human H5N1 Influenza Virus Replikin Gene Still Upregulated 2Lucid Expands Support Internationally: Dr. Colin Stahel appointed Director for Asia Pacific Region 2
(Date:8/20/2014)... Aug. 20, 2014  The second annual Biometrics ... Tampa, Florida on September ... Steven Rahman, Director, Technology and Strategy at Samsung, and ... The theme of this year,s event is Mobility ... "Biometrics UnPlugged: Mobility at the Crossroads ...
(Date:8/19/2014)... and Network-Level Science, , Imagine if we had the ... was responding to global changes in real time. Such ... multiple decades of information about ecological responses to environmental ... of different ecosystem types. , In fact, this ... Network, which will soon celebrate its 35th anniversary. , ...
(Date:8/19/2014)... have identified a biomarker strongly associated with basal-like ... resistant to many types of chemotherapy. The biomarker, ... for new therapeutics designed to treat this often ... taken from The Cancer Genome Atlas, molecular biologists ... powerful computational and bioinformatics techniques to detect patterns ...
Breaking Biology News(10 mins):Biometrics UnPlugged: Mobility at the Crossroads of Commerce & Privacy to Feature Interactive Sessions with Samsung and Experian 2This week from AGU: Long-term ecological research, predicting cholera outbreaks 2Biomarker in an aggressive breast cancer is identified 2Biomarker in an aggressive breast cancer is identified 3
... A new curriculum called The Great Diseases will ... high schools. The result of a collaboration between scientists ... the Boston Public Schools, the curriculum presents current threats ... studies. Funded by a grant from the National Institutes ...
... Cory, the former director of the Walter and Eliza ... been named the recipient of the 2009 Pearl Meister ... prize, created to recognise the accomplishments of outstanding female ... 5 November. The prize was founded by Rockefeller ...
... someday help clean up the earth. Converting methane ... prevent the potent greenhouse gas from entering the atmosphere. ... hydrogen source for fuel cells and yield other industrial ... in the laboratory, rests in identifying the starter link ...
Cached Biology News:Grant brings real-world science to Boston classrooms 2Grant brings real-world science to Boston classrooms 3Professor Suzanne Cory awarded 2009 Pearl Meister Greengard Prize 2RIT scientist shines laser light on methane in pursuit of clean fuel 2